In a filing, Avidity Biosciences Inc revealed its Chief Program Officer Gallagher Kathleen P. unloaded Company’s shares for reported $27549.0 on Jun 17 ’25. In the deal valued at $30.24 per share,911 shares were sold. As a result of this transaction, Gallagher Kathleen P. now holds 50,392 shares worth roughly $1.69 million.
Then, KATHLEEN GALLAGHER bought 911 shares, generating $27,148 in total proceeds.
Before that, Flanagan W. Michael sold 20,000 shares. Avidity Biosciences Inc shares valued at $657,694 were divested by the Chief Scientific Officer at a price of $32.88 per share. As a result of the transaction, Flanagan W. Michael now holds 80,195 shares, worth roughly $2.69 million.
A number of analysts have revised their coverage, including Bernstein’s analysts, who began to cover the stock in late June with a ‘”an Outperform”‘ rating. Wolfe Research began covering RNA with “an Outperform” recommendation on June 17, 2025. Raymond James started covering the stock on June 11, 2025. It rated RNA as “a Strong buy”.
Price Performance Review of RNA
On Monday, Avidity Biosciences Inc [NASDAQ:RNA] saw its stock jump 6.74% to $33.57. Over the last five days, the stock has gained 16.56%. Avidity Biosciences Inc shares have fallen nearly -21.07% since the year began. Nevertheless, the stocks have risen 15.44% over the past one year. While a 52-week high of $56.00 was reached on 06/09/25, a 52-week low of $21.51 was recorded on 04/09/25.
Levels Of Support And Resistance For RNA Stock
The 24-hour chart illustrates a support level at 32.43, which if violated will result in even more drops to 31.28. On the upside, there is a resistance level at 35.00. A further resistance level may holdings at 36.44.
How much short interest is there in Avidity Biosciences Inc?
A steep rise in short interest was recorded in Avidity Biosciences Inc stocks on 2025-06-13, growing by 0.56 million shares to a total of 16.34 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 15.79 million shares. There was a rise of 3.41%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 13, 2025 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $70 price target.
